Series of hepatitis B treatments enter Seoul National University Hospital, warning fierce competition

As Ildong Pharmaceutical’s ‘Besivo’ entered Seoul National University Hospital January after Gilead Sciences’ ‘Vemlidy’ last December, it has notified even fiercer competition in the chronic type B hepatitis market. The two products were also landed together on Severance Hospital last November.

According to the industry concerned, the Seoul National University Hospital Drug Committee approved ...